OncoPharm

We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared to chemo + pembrolizumab alone.

Also, a quick recap of ASCO GI earlier this month with mentions of zanidatamab and zolbetuximab.

Finally, a check-in on The Pitt.

This episode is the 2nd chapter in a broader presentation about putting together the puzzle pieces of oncology drug use. This chapter discusses examples of how oncology drug use changes over time.

Video & slides available at: https://youtu.be/Kxs0Xg9Ug_c?si=yOwEU1X-7mCPoQl5

A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?

Are we nearing the end of the Platinum Era in bladder cancer? A press release suggests enfortumab vedotin + pembrolizumab in a perioperative approach is better than the current standard of care: neoadjuvant cisplatin-based chemo followed by surgery. We eagerly await seeing this data.

Also, a subcutaneous amivantamab/hyaluronidase formulation is approved, which offers a much lower risk of infusion reactions - but some chances for dosing errors based on weights and available dosage forms.

ASH 2025 Highlights:

MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma

Paradigm: HMA + Ven vs. 7+3 or CPX-351

Denosumab safety & dosing in Multiply Myeloma and renal dysfunction

Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?